The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. director David S. Grayzel received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the issuer’s next annual stockholder meeting, subject to his continued service. Any proceeds from sales of shares issued upon exercise are to be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims ownership except for any pecuniary interest.
Q32 Bio Inc. director Mary Thistle received a grant of stock options representing 9,810 shares of common stock. These options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, she holds 9,810 options directly.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, as long as she continues serving on the board through that vesting date.
Q32 Bio Inc. director and ten percent owner Diyong Xu received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options expire on June 11, 2036.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Xu’s continued service. Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred to OrbiMed-related funds.
Q32 Bio Inc. director Sven Ante Lundberg received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase.
All 9,810 underlying shares will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Lundberg continues serving as a director through that vesting date.
Q32 Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders representing 11,833,800 common shares out of 15,629,463 entitled shares, or 75.71% of outstanding shares as of April 15, 2026, were present in person or by proxy.
All three Class II director nominees – Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. – were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding, advisory basis, the compensation of the company’s named executive officers. The report was signed on behalf of the company by Chief Executive Officer Jodie Morrison.
Q32 Bio Inc. disclosed that Atlas Venture Opportunity Fund III, L.P. holds 625,000 shares of its common stock in an initial beneficial ownership report. Related general partners Atlas Venture Associates Opportunity III, L.P. and Atlas Venture Associates Opportunity III, LLC disclaim beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. ownership disclosure: a group of affiliated entities led by Biotechnology Value Fund, L.P. and related entities reported coordinated holdings representing up to 2,367,524 shares (aggregate) and certain beneficial ownership positions in Q32 Bio common stock. As of the close of business on June 4, 2026, BVF held 1,248,973 shares (5.3%), BVF2 held 929,003 shares (3.9%), and Biotechnology Value Trading Fund OS held 155,156 shares (<1%).
The filing also discloses 150,000 pre-funded warrants exercisable into shares; an Ownership Limit of 9.99% restricts exercises, limiting exercisable pre-funded warrants to 17,524 shares for the reporting group as of June 4, 2026. Several entities in the group disclaim beneficial ownership of other group members' shares; BVF GP, BVF2 GP, BVF GPH, Partners, BVF Inc. and Mark N. Lampert are named as related controlling or deemed owners in the schedule.
Q32 Bio Inc. reporting persons led by RA Capital Management, L.P. disclose beneficial ownership of 2,332,457 shares of common stock, representing 9.8% of the class. The percentage is calculated using May 1, 2026 outstanding shares (16,956,415) plus 6,725,000 shares issued in a private placement that closed on May 28, 2026. The filing states the Fund "delegated to RA Capital the sole power to vote and the sole power to dispose" of the reported shares and that the Reporting Persons "disclaim beneficial ownership" of the securities except as required for Section 13(d) reporting.
Q32 Bio Inc. director and 10% owner Diyong Xu reported indirect purchases totaling 1,875,000 shares of common stock at $8.00 per share. The shares were acquired by affiliated OrbiMed investment funds in a private placement directly from Q32 Bio, with one fund’s indirect holdings reaching 3,502,987 shares after the transactions.
Q32 Bio Inc. reported significant insider buying by OrbiMed-affiliated investment entities. On May 28, 2026, these entities purchased a total of 1,875,000 shares of Q32 Bio common stock at $8.00 per share in a private placement directly from the company.
Following these transactions, one OrbiMed-related account holds 3,502,987 shares of common stock and another holds 625,000 shares, both reported as indirect ownership. The OrbiMed entities, which are 10% owners and have a board representative at Q32 Bio, disclaim beneficial ownership beyond their pecuniary interests.